Ionis Pharmaceuticals and Biogen reported encouraging Phase 1 results for salanersen, a potent antisense oligonucleotide developed for spinal muscular atrophy (SMA) that builds on the mechanism of Biogen's SPINRAZA but with enhanced potency. Positive interim data support the progression into Phase 1/2 clinical trials, underscoring salanersen’s potential as a formidable new therapeutic for SMA patients, aiming for improved efficacy in this severe neuromuscular disorder.